AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
November 12, 2024 4:24 PM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $362.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "When has three patients worth of data ever been the 'be all and end all'? Context matters, and while this MariTide data... More
Barclays Reiterates Equalweight Rating on Amgen (AMGN)
November 12, 2024 4:23 PM ESTBarclays analyst Carter Gould reiterated an Equalweight rating and $315.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We reviewed the supplemental MariTide (AMG133) phase 1 data, highlighted by (1) BMD loss (as measured by DEXA scan across femur and hip) at higher doses (420mg), and (2) notable heart rate excursions (25bpm at the 280mg dose). While far from... More
Jefferies on Amgen (AMGN): 'Thoughts on Phase I bone data for AMG-133 - seems non-issue'
November 12, 2024 3:44 PM ESTJefferies analyst Michael Yee reiterated a Buy rating and $380.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We reviewed public data from Phase I AMG-133 showing add'l measurements of BMD (bone density) from obesity pts - which could be interpreted... More
Cantor Fitzgerald Locates Data on Amgen (AMGN) Hidden in Tables for MariTide's Data
November 12, 2024 2:48 PM ESTCantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $405.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "We just came across a new piece of information from MariTide's Ph1, and we found a big surprise... The supplemental appendix file seems to show bone mineral... More
